← All trials
NCT06517173
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 31, 2025
- First posted
- Jul 24, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 998
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- NeuroDawn Pharmaceutical Co., Ltd.Collaborator
- Capital Medical UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.